Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway

Diabetologia. 1993 Jun;36(6):570-3. doi: 10.1007/BF02743276.

Abstract

To determine the potential for differential release of islet amyloid polypeptide and insulin, we performed studies in rat islet monolayer cultures under conditions known to impair regulated beta-cell secretion. In inhibiting concentrations of epinephrine or the absence of calcium, islet amyloid polypeptide was secreted through a constitutive pathway while insulin was not. These findings suggest a mechanism for persistent islet amyloid polypeptide secretion and amyloid accumulation when regulated insulin release is impaired as in Type 2 (non-insulin-dependent) diabetes mellitus and insulinomas.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amyloid / metabolism*
  • Animals
  • Animals, Newborn
  • Calcium / pharmacology
  • Cells, Cultured
  • Epinephrine / pharmacology*
  • Glucose / pharmacology*
  • Insulin / metabolism*
  • Insulin Secretion
  • Islet Amyloid Polypeptide
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / metabolism*
  • Kinetics
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Amyloid
  • Insulin
  • Islet Amyloid Polypeptide
  • Glucose
  • Calcium
  • Epinephrine